ND: |
ME16582688 |
PMID: |
16582688 |
CED: |
20060403 |
Autoren: |
Hogenmiller MS; Lozada CJ |
Titel: |
An update on osteoarthritis therapeutics. |
Quelle: |
Current opinion in rheumatology; VOL: 18 (3); p. 256-60 /200605/ |
PM: |
Print |
SU: |
IM |
Sprache: |
English |
CY: |
United States |
JID: |
9000851 |
ISSN: |
1040-8711 |
CO: |
CORHES |
Institution: |
aDepartment of Medicine, Jackson Memorial Hospital bDepartment of Medicine, Miami VA Medical Center cDivision of Rheumatology, University of Miami Miller School of Medicine, Miami, Florida, USA. |
DT: |
Journal Article |
AB: |
PURPOSE OF REVIEW: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. RECENT FINDINGS: The past year has led to a reassessment of the role of cyclo-oxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. SUMMARY: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief. |